Disease Landscape and Forecast Insights

Immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab ± ipilimumab, nivolumab / relatlimab FDC) and BRAF/MEK inhibitor combinations (e.g., vemurafenib plus cobimetinib) have greatly…

Disease stage, primary tumor resectability, and BRAF mutation status are some of the key parameters influencing the treatment of malignant melanoma. For patients with BRAF mutations, BRAF/MEK…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…

Immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab ± ipilimumab, and nivolumab plus relatlimab) and BRAF/MEK inhibitor combinations (e.g., vemurafenib plus cobimetinib) have greatly…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key malignant melanoma patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

The introduction of immune checkpoint inhibitors such as Keytruda (Merck & Co.), Opdivo + Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; U.S. only), as well as BRAF / MEK…

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; U.S. only), as well as BRAF/MEK inhibitor…

Disease stage, primary tumor resectability, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma patients. BRAF/MEK inhibitor combination regimens,…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

The malignant melanoma market in Europe has become crowded. Small-molecule targeted therapies such as Novartis’s Tafinlar and Mekinist, monoclonal antibodies including Merck & Co.’s Keytruda…

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/MEK …